Stand Up to Cancer (SU2C) and Mirati Therapeutics said on Monday that Mirati has awarded $4 million to SU2C to advance treatment for KRAS-mutant cancers.
Stand Up to Cancer (SU2C) and Mirati Therapeutics said on Monday that Mirati has awarded $4 million to SU2C to advance treatment for KRAS-mutant cancers.